Sign in
Taking people in South KoreaNo phase

Comparing Two Blood-Thinner Durations After Carotid Stenting in High Bleeding Risk Adults

Compares two durations of blood-thinner treatment after carotid stenting in people with high bleeding risk.

Key facts

Who runs it
Woo-Keun Seo
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients
Status
Recruiting
People taking part
1,556 people, planned
Started
15 Jul 2024
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Intervention 1(DAPT): Drug: Aspirin 100mg + Clopidogrel 75mg. Intervention 2(SAPT): Drug: Asprin 100mg or Clopidogrel 75mg
Record updated
14 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a narrowed carotid artery (in the neck) who are having or have had a stent placed and who have a high risk of bleeding. It compares two lengths of treatment with two blood-thinning drugs.

Age
19 years or older
Sex
All sexes can join.
Disease stage
Carotid artery narrowing greater than 50% with symptoms, or greater than 70% without symptoms. A carotid stent is planned or already placed. High bleeding risk, with at least one of the listed bleeding-risk factors.
Earlier treatment
After the stent, everyone takes aspirin 100 mg and clopidogrel 75 mg daily for 30 days. Only people without major heart, brain or bleeding events in those 30 days continue.

Main reasons for not taking part

  • A major heart, brain or bleeding event within 30 days after the stent
  • Stopping the two-drug treatment within 30 days after the stent
  • Coronary or other vascular stenting or reopening of a vessel within 1 year
  • Allergy to aspirin or clopidogrel
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients ≥19 years
  • Symptomatic patients with carotid artery stenosis* greater than 50% and asymptomatic patients with carotid artery stenosis* greater than 70% who are scheduled to undergo or who have undergone carotid artery stenting
  • High bleeding risk is defined as a Bleeding Academic Research Consortium type 3 or 5 bleeding risk of ≥4% at 1 year or a risk of an intracranial hemorrhage (ICH) of ≥1% at 1 year, Patients who meet at least one of the criteria for high bleeding risk** below; The degree of stenosis is determined using the method performed in the North American Symptomatic Carotid Endarterectomy Trial; Criteria for high bleeding risk (≥ 1); Incidence of non-access site bleeding within 12 months prior to stenting (gastrointestinal tract or hematuria); Presence of BARC type 3 or 5 bleeding regardless of the onset time, but the cause has not been completely cured; Adults aged ≥75 years; Thrombocytopenia < 100,000/mm3 (based on the screening test); Blood clotting disorders that increase bleeding (Von Willebrand disease, factor VII, VIII, IX, and XI deficiency); Patients with anemia defined as hemoglobin <12g/dL in men and <11g/dL in women or patients who donated blood within 4 weeks (based on the screening test); Patients received steroids or NSAIDs for ≥4 weeks; Patients with active malignancy (except for nonmelanoma skin cancer); Renal disease (dialysis, transplantation, Estimated Glomerular Filtration Rate < 60ml/min per 1.73m2); Liver disease (cirrhosis with portal hypertension); Cerebral microbleeds ≥ 5; Stroke or transient ischemic attacks within 6 months or Transient amaurosis fugax; Incidence of nontraumatic intracerebral hemorrhage regardless of duration or incidence of traumatic intracerebral hemorrhage within 12 months

Who cannot take part

  • Coronary artery stenting or other vascular stenting or vascular recanalization within 1 year (Revascularization surgery that requires CABG(Coronary Artery Bypass Graft) and other dual antiplatelet therapy)
  • Patients requiring administration of other antiplatelet therapies
  • Incidence of net clinical events, including cardiovascular and cerebrovascular accidents or major bleeding events, within 30 days following carotid artery stenting
  • Discontinuation of dual antiplatelet therapy within 30 days after carotid stent implantation (However, use of a single antiplatelet therapy within 7 days due to acute infection and trauma is allowed, but dual antiplatelet therapy must be administered at 28 to 30 days after carotid stent implantation)
  • Aspirin or clopidogrel hypersensitivity
  • Pregnant or breastfeeding women (Women of childbearing need to check for pregnancy using urine or blood tests before enrollment, and use appropriate contraception methods during the clinical trial period)
  • Patients requiring anticoagulation for ≥12 months
  • Patients who are participating in another intervention clinical trial

Where in South Korea

  • Samsung Medical CenterSeoul, South KoreaContact: Woo-Keun Seo, Ph.DTaking people

About the trial

What the trial wants to find out

The optimal duration of dual antiplatelet therapy (DAPT) after carotid artery stenting (CAS) in patients at high bleeding risk (HBR) has not been established in randomized controlled trials. Current practice largely extrapolates from percutaneous coronary intervention (PCI) trials, but anatomical and procedural differences between coronary and carotid arteries limit the validity of this approach.

Read full original descriptionShow less

The CHET trial is a multicenter, randomized, open-label, superiority trial designed to compare two DAPT durations after CAS in patients at HBR. After CAS, all eligible patients receive aspirin (100 mg daily) and clopidogrel (75 mg daily) for a 30-day enrichment period. Patients who remain free of net clinical events at day 30 are randomized 1:1 to either single antiplatelet therapy (SAPT; aspirin 100 mg or clopidogrel 75 mg daily, at the treating physician's discretion) for 11 months, or continued DAPT for 11 months.

The primary hypothesis is that abbreviated DAPT followed by SAPT is superior to prolonged DAPT in reducing clinically significant bleeding (Bleeding Academic Research Consortium [BARC] type 2, 3, or 5) from 30 days to 12 months after CAS, while maintaining noninferiority in net clinical outcomes (composite of nonfatal stroke, nonfatal myocardial infarction, cardiovascular death, and major bleeding [BARC type 3 or 5]).

A total of 1,556 participants (778 per group) will be enrolled across multiple comprehensive stroke centers in the Republic of Korea. Patients will be followed at 5 and 11 months after randomization, with subsequent annual follow-up (in-person or by telephone) until study completion to capture long-term clinical events.

The 2 groups in the trial

  • Single antiplatelet therapy (SAPT) group with aspirin or clopidogrelTreatment being tested

    1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)

    Treatment: Intervention 1(DAPT): Drug: Aspirin 100mg + Clopidogrel 75mg. Intervention 2(SAPT): Drug: Asprin 100mg or Clopidogrel 75mg

  • Dual antiplatelet therapy (DAPT) with aspirin and clopidogrelExisting treatment, for comparison

    1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)

    Treatment: Intervention 1(DAPT): Drug: Aspirin 100mg + Clopidogrel 75mg. Intervention 2(SAPT): Drug: Asprin 100mg or Clopidogrel 75mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Trial to Obtain the Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients
Plain-language title
Comparing Two Blood-Thinner Durations After Carotid Stenting in High Bleeding Risk AdultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
14 July 2026